Thursday, June 02, 2022

Baudax Bio (BXRX)
BX2000 Phase I First Cohort Dosed

Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase I Neuromuscular Blocking Agent (NMB) trial advances.  The BX2000 trial is a double-blind, placebo-controlled dose escalation study with up to 10 dosing cohorts. Each cohort will enroll 8 patients and the Company yesterday announced the first cohort has been dosed.  The study will evaluate safety, pharmacokinetics, and time course of the neuromuscular blocking profile.

Baudax Bio now has two novel NMBs in the clinic. BX1000 is a rapid onset, intermediate acting agent that has completed the dose escalation Phase I and is currently moving toward Phase II. BX2000 is a rapid onset, ultra-short acting agent with Phase I dose escalation enrollment expected to be completed by early 2023.

…

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.